Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Appropriate Antibiotic Use for Acute Otitis Media
Your Article Summary
See Latest ArticlesImmediate Microsurgical Reconstruction After Tumor Ablation Predicts Survival Among Patients with Head and Neck Carcinoma
Annals of Surgical Oncology, 10/23/09
Mucke T et al. – Reconstruction of defects, especially in patients presenting with higher tumor stages, is not associated with shorter overall survival rates, as revealed in this study, and should be considered when functional deficits due to tumor ablation can be expected postoperatively.
Thomas Mücke, 10/24/09
| This article was initially thought to analyze tumor related factors. Surprisingly microsurgical free flap surgery seems to be an independent prognostic factor and justifies long-lasting operations which are associated with the following advantages: 1. reconstruction and rehabilitation of patients 2. increasing the quality of life 3. immeadiate reconstruction is easier than a second stage procedure with the presence of scars 4. wound healing is shorter 5. most important: The overall survival is increased. From the surgical point of view there seem to be some more advantages, but this is the first article which shows that tumor patients benefit from reconstructive preocedures, although associated complications and morbidities should be kept in mind. |
Today in Head and Neck...keeping you current
Receive free subspecialty "5-minute updates" via email
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: Results from a phase II prospective trial
Journal of Clinical Oncology, 11/25/09
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
The Lancet Oncology - Online First, 11/12/09
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
Annals of Oncology, 11/10/09
Article Search
Sponsor